Ovarian cancer | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

The most frequent cause of death in women with gynecological cancer diagnoses is ovarian cancer. Additionally, it is the seventh most frequent cause of death for women overall. Since the majority of patients are found to have this illness at an advanced stage, the prognosis is poor. About 21,750 new cases of ovarian cancer, or 1.2% of all cancer cases, will be diagnosed in 2020. It is estimated to be directly responsible for 13,940 fatalities. The estimated 5-year relative survival rate is 48.6%. When the 5-year survival rate drops to 30.2% from 92.6% if detected at an early stage of local dissemination, 15.7% of ovarian cancer cases are discovered locally and 58% are diagnosed with metastases. Along with the increase in older women, ovarian cancer infection rates are also rising. This population growth could have an impact on the ovarian cancer drug market. Governments thus increase access to medical care and treatment.

Description

The most frequent cause of death in women with gynecological cancer diagnoses is ovarian cancer. It is also the seventh most frequent cause of death for women overall. Since the majority of patients are found to have this illness at an advanced stage, the prognosis is poor. The situation is significantly worsened by the screening tests currently in use's low predictive value. Comprehensive gynecological evaluation, transvaginal ultrasound, and laboratory markers like the cancer antigen-125 (CA-125) assay are the main early detection measures that have not significantly decreased the morbidity or mortality of this malignancy. The standard treatments for this gynecological cancer are surgery and platinum-based chemotherapy, but over the past ten years, anti-angiogenic bevacizumab, and poly (ADP-ribose) polymerase (PARP) inhibitors have become more common.

Ovarian cancer (Epidemiology)

In 2020, there will be 21,750 new cases of ovarian cancer, or 1.2% of all cancer cases. It is estimated that 13,940 fatalities can be directly attributed to it. 48.6% is the anticipated 5-year relative survival rate. When the 5-year survival rate drops to 30.2% from 92.6% if detected at an early stage of local dissemination, 15.7% of ovarian cancer cases are found locally and 58% are diagnosed with metastases. Age-adjusted to the US standard population of 2000, there was an incidence rate of 11.1 per 100,000 people on average from 2012 to 2016. The highest incidence was found in non-Hispanic whites (11.6 per 100,000), followed by non-Hispanic Blacks (10.3 per 100,000), American Indians and Alaska Natives (10.1 per 100,000), Hispanics (10.1 per 00,000), and Asian and Pacific Islanders. Ninety% of cases of ovarian cancer are of the serous subtype, which is more common. The rate of ovarian cancer cases that are newly diagnosed is decreasing with age, according to statistical analysis models.

Ovarian cancer -Current Market Size & Forecast Trends

The market for ovarian cancer treatment is expected to grow significantly, with estimates indicating a current value of approximately USD 2.72 billion in 2023. This market is projected to expand at a compound annual growth rate (CAGR) of 23.8%, potentially reaching around USD 21.92 billion by 2032. Key drivers of this growth include the rising incidence of ovarian cancer, advancements in treatment options such as PARP inhibitors and immunotherapies, and an increasing focus on early detection and personalized medicine. The North American market is anticipated to dominate due to high healthcare expenditure and ongoing research initiatives, while the Asia-Pacific region is expected to exhibit the fastest growth due to a large patient population and improving healthcare infrastructure. Overall, the ovarian cancer market is well-positioned for substantial expansion through 2035, supported by innovative therapies and increasing awareness of the disease.

Along with the increase in older women, ovarian cancer infection rates are also rising. This population growth could have an impact on the market for ovarian cancer treatments. Governments thus widen access to medical care and treatment. Ovarian cancer is primarily treated surgically. It is used for staging and cytoreduction (debulking), but it has the potential to be curative in diseases that are limited to the ovaries. For women with early-stage invasive epithelial ovarian cancers, lesions with low potential for malignancy (e.g., adenocarcinomas), unilateral salpingo-oophorectomy with preservation of the uterus and contralateral ovary is an option (e.g., lesions with histologically abnormal cells that are thought to have a low likelihood of progressing to cancer), germ cell tumors, or sex cord-stromal tumors. Postsurgical adjuvant chemotherapy is advised for stage II and late-stage cases, but it is typically not indicated for disease that is limited to the ovaries. The current standard of care for late-stage tumors is postsurgical intraperitoneal and intravenous chemotherapy, which improves the median survival rate by 12 months when compared to intravenous chemotherapy alone. Presurgical chemotherapy, or neoadjuvant chemotherapy, has no advantages over chemotherapy administered after surgery. The evidence does not support routine maintenance chemotherapy after the initial course. As people's awareness of health issues grows, experts predict that sales of drugs like Maveropepimut S (IMV), Pazopanib (Votrient), and others will soar. Ongoing advancements in ovarian cancer treatments are anticipated to benefit the pharmaceutical industry. Research on ovarian cancer therapies is ongoing, and some of the treatments that are currently being tested might be put on the market soon.

Report Highlights

Ovarian cancer - Current Market Trends

Ovarian cancer - Current & Forecasted Cases across the G8 Countries

Ovarian cancer - Market Opportunities and Sales Potential for Agents

Ovarian cancer - Patient-based Market Forecast to 2035

Ovarian cancer - Untapped Business Opportunities

Ovarian cancer - Product Positioning Vis-a-vis Competitors' Products

Ovarian cancer - KOLs Insight